PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Simple item page
dc.contributor.authorBektur, C
dc.contributor.authorNurgozhin, T
dc.contributor.authorAbdukhakimova, D
dc.creatorC, Bektur
dc.date.accessioned2017-12-13T05:02:22Z
dc.date.available2017-12-13T05:02:22Z
dc.date.issued2015-11-01
dc.description.abstractHepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV patients in Kazakhstan.en_US
dc.identifierDOI:10.1016/j.jval.2015.09.2209
dc.identifier.citationC Bektur, T Nurgozhin, D Abdukhakimova, PGI28 - Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan, In Value in Health, Volume 18, Issue 7, 2015, Page A627en_US
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301515042850
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2861
dc.language.isoenen_US
dc.publisherValue in Healthen_US
dc.relation.ispartofValue in Health
dc.rightsOpen Access - the content is available to the general publicen_US
dc.rights.licenseCopyright © 2015 Published by Elsevier Inc.
dc.titlePGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstanen_US
dc.typeArticleen_US
elsevier.aggregationtypeJournal
elsevier.coverdate2015-11-01
elsevier.coverdisplaydateNovember 2015
elsevier.identifier.doi10.1016/j.jval.2015.09.2209
elsevier.identifier.eid1-s2.0-S1098301515042850
elsevier.identifier.piiS1098-3015(15)04285-0
elsevier.issue.identifier7
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA627
elsevier.volume18
workflow.import.sourcescience

Files

Collections

Articles